Psychedelics.media
  • News
  • Research
  • Policy & Regulation
  • Business
  • Health & Therapy
  • Culture
  • Opinion
No Result
View All Result
Psychedelics.media
  • News
  • Research
  • Policy & Regulation
  • Business
  • Health & Therapy
  • Culture
  • Opinion
No Result
View All Result
Psychedelics.media
No Result
View All Result
Emyria Takes Psychedelic Medicine to Sydney with New Clinic

Emyria Takes Psychedelic Medicine to Sydney with New Clinic

Psychedelics.Media Team by Psychedelics.Media Team
September 8, 2026
in Business
Summarize with ChatGPTShare to Facebook

Emyria (ASX: EMD) is preparing to open its first Sydney clinic in September, with the company saying key operational milestones have now been completed ahead of launch.

The clinic at Matilda Nepean Private Hospital in Kingswood will give Emyria its first presence in New South Wales and expand its clinical network into Australia’s most populous state.

Emyria said the clinic fit-out is complete, with four dedicated treatment rooms furnished and equipped ahead of the planned opening.

The company has also recruited and trained around 20 Sydney-based therapists and four psychiatrists. Two of the Sydney psychiatrists have obtained Authorised Prescriber status, supporting Emyria’s ability to commence treatments once the clinic opens.

Hospital, pharmacy and medication supply arrangements have also been secured, including a formal agreement with Matilda Nepean Private Hospital.

First patients approved for treatment

Emyria said the first patients have already been approved for treatment through the workers compensation pathway and are expected to begin treatment shortly after the clinic opens.

The company has not disclosed how many patients have been approved.

The Sydney clinic will add to Emyria’s existing clinical operations across Queensland, Victoria and Western Australia, expanding the company’s access to patients in another major Australian healthcare market.

Expanding access to emerging mental health treatments

Emyria describes its clinical model as focused on evidence-based intensive mental health care, including emerging therapies such as psychedelic-assisted therapy.

The company’s current work includes assisted therapy programs for conditions including post-traumatic stress disorder (PTSD) and treatment-resistant depression.

Its broader model combines direct clinical services with real-world data collection and treatment development. Emyria says data gathered through its clinical operations informs its drug and therapy development programs.

The company is now approaching the Sydney launch with the main operational components already in place, including the clinical team, treatment facilities, Authorised Prescribers and medication and healthcare partnerships.

With the clinic expected to open in September, the Sydney site will become Emyria’s first NSW operation and another component of its growing national clinical network.

Tags: AustraliaAuthorised PrescribersEMDEmyriaMental HealthNew South WalesPsychedelic MedicinePsychedelic-assisted therapyPTSDSydneyTreatment-Resistant Depression
SummarizeShare235
Psychedelics.Media Team

Psychedelics.Media Team

Related Stories

BioAdaptives Moves into Psychedelic Drug Development with Proposed Xycota Acquisition

BioAdaptives Moves into Psychedelic Drug Development with Proposed Xycota Acquisition

by Psychedelics.Media Team
November 6, 2026
0

US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...

PharmAla Advances ALA-002 Drug Development with Canadian GMP Manufacturing Agreement

PharmAla Advances ALA-002 Drug Development with Canadian GMP Manufacturing Agreement

by Psychedelics.Media Team
November 6, 2026
0

Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...

Definium Therapeutics to Present Results From Three Phase 3 LSD Trials at Psychiatry Congress

Definium Therapeutics to Present Results From Three Phase 3 LSD Trials at Psychiatry Congress

by Psychedelics.Media Team
November 5, 2026
0

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug candidate, DT120 ODT, at the 2026 Neuroscience Education...

Enveric Biosciences Reports New Brain Activity Data for Psychedelic-Derived Drug Candidate

Enveric Biosciences Reports New Brain Activity Data for Psychedelic-Derived Drug Candidate

by Psychedelics.Media Team
November 5, 2026
0

New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...

Next Post
Emyria Selected by FDA to Present at Psychedelic Medicines Hearing

Emyria Selected by FDA to Present at Psychedelic Medicines Hearing

Psychedelics.media

Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.

Recent Posts

  • BioAdaptives Moves into Psychedelic Drug Development with Proposed Xycota Acquisition
  • PharmAla Advances ALA-002 Drug Development with Canadian GMP Manufacturing Agreement
  • Definium Therapeutics to Present Results From Three Phase 3 LSD Trials at Psychiatry Congress

Categories

  • Business
  • Culture
  • Health & Therapy
  • Leaflit
  • News
  • Opinion
  • Policy & Regulation
  • Research

Free Weekly Newsletter

    • Subscribe
    • Advertise
    • Contact Us

    © 2026 Psychedelics.media - A division of Dot Media Corp.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    No Result
    View All Result
    • Home
    • News
    • Business
    • Policy & Regulation
    • Research
    • Health & Therapy
    • Opinion
    • Contact

    © 2026 Psychedelics.media - A division of Dot Media Corp.

    Not enough quota to unlock this post
    Unlock left : 0
    Are you sure want to cancel subscription?